drugset / Trial / NCT00957268
Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
Non-randomizedParallel-groupOpen-label
Summary
The purpose of this study is to determine the pharmacokinetic and safety profile of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
Timeline
- Start
- 2009-09
- Primary completion
- 2013-11
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alogliptin | Unknown | 12.5 mg | Oral |
| Subject | Alogliptin | Unknown | 25 mg | Oral |